Maze Therapeutics, Inc. (MAZE) Stock Statistics & Valuation Metrics

Maze Therapeutics, Inc. has a market cap or net worth of $1.73B. The enterprise value is $1.24B.

Maze Therapeutics, Inc. has 55,345,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

Maze Therapeutics, Inc.’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -37.67%.

The current PE Ratio of Maze Therapeutics, Inc. is ―. Maze Therapeutics, Inc.’s PEG ratio is 0.00338.

In the last 12 months, Maze Therapeutics, Inc. had revenue of 0.00 and earned -131.12M in profits. Earnings per share was -3.05.

In the last 12 months, operating cash flow was -121.54M and capital expenditures -588.00K, giving a free cash flow of -122.13M billion.

Maze Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Maze Therapeutics, Inc. upcoming earnings date is Aug 18, 2026, Before Open (Confirmed).

Maze Therapeutics, Inc. as a current ratio of 15.50, with Debt / Equity ratio of 17.92%

In the past 12 months, Maze Therapeutics, Inc. has paid 0.00 in taxes.

Maze Therapeutics, Inc. EV to EBITDA ratio is -12.54, with an EV/FCF ratio of -14.32.

Maze Therapeutics, Inc. has $352.38M in cash and marketable securities with $61.22M in debt, giving a net cash position of $291.16M billion.

Gross margin is 92.04%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Maze Therapeutics, Inc. is $70.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy